Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.

Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: paliperidone palmitate
Drug: haloperidole
Drug: quetiapine
Drug: risperidone
Drug: olanzapine
Drug: aripiprazole
Drug: paliperidone
Drug: perphenazine

First Posted Date: 2010-07-07

Last Posted Date: 2015-04-24

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 450

Registration Number: NCT01157351

Effect of Olanzapine on Sleep Electroencephalogram (EEG) in Schizophrenia Patients

Phase 4

Completed

Conditions: Schizophrenia
Sleep

Interventions: Drug: Olanzapine

First Posted Date: 2010-06-23

Last Posted Date: 2010-06-23

Lead Sponsor: Central Institute of Psychiatry, Ranchi, India

Target Recruit Count: 25

Registration Number: NCT01149577

Locations: 🇮🇳
Central Institute of Psychiatry, Ranchi, Jharkhand, India

Comparison of Olanzapine and Metoclopramide For Treatment Of bReakThrough Emesis

Phase 2

Terminated

Conditions: Emesis

Interventions: Drug: olanzapine
Drug: metoclopramide

First Posted Date: 2010-06-22

Last Posted Date: 2016-05-11

Lead Sponsor: Karin Jordan

Target Recruit Count: 23

Registration Number: NCT01148264

Locations: 🇩🇪
Martin-Luther-University Halle-Wittenberg, Department for Oncology and Hematology, Ernst-Grube-Strasse 40, Halle (Saale), Sachsen-Anhalt, Germany

A Long-Term, Open-Label, Study on Schizophrenia

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: LY2140023
Drug: Aripiprazole
Drug: Risperidone
Drug: Quetiapine

First Posted Date: 2010-05-25

Last Posted Date: 2013-01-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1210

Registration Number: NCT01129674

Locations: 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine

Clozapine and Olanzapine Treatment of Aggression

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: Clozapine
Drug: Haloperidol

First Posted Date: 2010-05-14

Last Posted Date: 2010-05-14

Lead Sponsor: Nathan Kline Institute for Psychiatric Research

Target Recruit Count: 110

Registration Number: NCT01123408

Locations: 🇺🇸
Nathan Kline Institute, Orangeburg, New York, United States

Standard Comprehensive Intervention to Treat First-episode Schizophrenia

Not Applicable

Conditions: Schizophrenia

Interventions: Drug: risperidone
Drug: Aripiprazole
Drug: olanzapine

First Posted Date: 2010-01-27

Last Posted Date: 2010-01-27

Lead Sponsor: Peking University

Target Recruit Count: 600

Registration Number: NCT01057849

Locations: 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China
🇨🇳
Zhongnan University Xiangya Second Hospital, Changsha, Hunan, China
🇨🇳
Beijing Huilongguan Hospital, Beijing, Beijing, China

and more 3 locations